Theriva Biologics Faces Critical Juncture Following Deep Workforce Cuts

Financial Metrics Paint Dire Picture

Theriva Biologics has initiated a severe corporate restructuring program, eliminating 32% of its global workforce—a reduction of seven positions—in a dramatic effort to preserve its dwindling cash reserves. The biopharmaceutical firm is confronting a liquidity crisis that demands immediate and substantial intervention.

The company’s latest quarterly report reveals a deeply troubling financial trajectory that has severely eroded investor confidence. Administrative and general expenses skyrocketed by 662% to $11.2 million, while available cash reserves diminished rapidly from $12.1 million to $9.5 million within just weeks. Market capitalization has collapsed to a mere $3.99 million, with shares trading at approximately $0.42—reflecting widespread market skepticism about the company’s prospects.

Strategic Shift to Prioritize Lead Candidate